title: A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome.
abstract: OBJECTIVE
  To determine the effect of exogenous LH dosage on IVF outcome.
  
  
  METHODS
  Single-blinded (assessor-blinded) study with random assignment of treatment groups.
  
  
  METHODS
  Human Assisted Reproduction Unit, Rotunda Hospital, Dublin, Ireland.
  
  
  METHODS
  Infertile normogonadotropic women undergoing their first cycle of IVF were studied.
  
  
  METHODS
  Patients were randomized to gonadotropin drugs with varying doses of LH per ampule: recombinant FSH containing no LH (group 0, n = 39), urinary FSH containing <1 IU of LH per ampule (group 1, n = 30), hMG containing 25 IU of LH per ampule (group 25, n = 30), and hMG containing 75 IU of LH per ampule (group 75, n = 29). The FSH dose was kept constant at 75 IU per ampule. A long-protocol GnRH-analog regimen was used.
  
  
  METHODS
  Dose and duration of gonadotropin stimulation, follicle and oocyte numbers, implantation rate, and pregnancy rate.
  
  
  RESULTS
  The median duration of ovarian stimulation; median number of gonadotropin ampules used; serum E2 levels; and numbers of follicles, oocytes, and embryos were similar among the four groups. Median LH levels on the day of hCG administration, however, differed significantly. Live birth rates per cycle differed markedly, but statistical significance was not achieved (23%, 7%, 20%, and 31% for groups 0, 1, 25, and 75, respectively). A significant trend in implantation rates was noted with increasing LH dosage of the urinary preparations (19%, 10%, 18%, and 28% for groups 0, 1, 25, and 75, respectively).
  
  
  CONCLUSIONS
  In the present study, although the residual endogenous LH after down-regulation was adequate for ovarian response and E2 synthesis, the addition of exogenous LH improved implantation. An FSH/LH ratio of 75/75 IU per ampule appeared to be the optimum dose.
authors.affiliation: Centre for Reproductive Medicine, University of Bristol, 4 Priory Road, Clifton, Bristol BS8 1TY, United Kingdom. u.d.gordon@bristol.ac.uk
authors.forename: U D
authors.initials: UD
authors.lastname: Gordon
authors.forename: R F
authors.initials: RF
authors.lastname: Harrison
authors.forename: M
authors.initials: M
authors.lastname: Fawzy
authors.forename: B
authors.initials: B
authors.lastname: Hennelly
authors.forename: A C
authors.initials: AC
authors.lastname: Gordon
mesh_terms: D000328:Adult; D002452:Cell Count; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D010064:Embryo Implantation; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000652:urine; D006801:Humans; D007986:Luteinizing Hormone / Q000008:administration & dosage* / Q000097:blood; D009865:Oocytes; D006080:Ovarian Follicle / Q000033:anatomy & histology; D010062:Ovulation Induction; D011247:Pregnancy; D011446:Prospective Studies
chemical_list: D006063:Chorionic Gonadotropin; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone